FindTrial
Sign In

9vHPV vaccine

BIOLOGICAL10 trials

Sponsors

Merck Sharp & Dohme LLC, Takeda

Conditions

Adenocarcinoma in SituAnal CancerAnal Intraepithelial NeoplasiaCondylomata AcuminataCoronavirus Disease (COVID-19)Dengue FeverGenital WartsPapillomavirus Infections

Phase 3

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
CompletedNCT01651949
Merck Sharp & Dohme LLCAnal Cancer, Anal Intraepithelial Neoplasia, Genital Warts
Start: 2012-10-29End: 2014-08-04Updated: 2018-11-27
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
CompletedNCT03546842
Merck Sharp & Dohme LLCAdenocarcinoma in Situ, Condylomata Acuminata, Papillomavirus Infections +3
Start: 2018-06-29End: 2019-01-29Updated: 2020-02-25
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Active, not recruitingNCT04199689
Merck Sharp & Dohme LLCPapillomavirus Infections
Start: 2020-02-27End: 2028-08-31Updated: 2025-03-25
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
CompletedNCT04313244
TakedaDengue Fever
Start: 2021-05-15End: 2022-07-19Updated: 2024-02-07
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Active, not recruitingNCT04708041
Merck Sharp & Dohme LLCPapillomavirus Infections
Start: 2021-03-15End: 2029-10-23Target: 700Updated: 2025-04-20
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
CompletedNCT04772534
Merck Sharp & Dohme LLCPapillomavirus Infections
Start: 2021-05-17End: 2024-04-06Updated: 2025-05-30
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
CompletedNCT05119855
Merck Sharp & Dohme LLCCoronavirus Disease (COVID-19), Papillomavirus Infections
Start: 2022-03-28End: 2023-12-12Updated: 2026-02-05
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Active, not recruitingNCT05285826
Merck Sharp & Dohme LLCPapillomavirus Infections
Start: 2022-02-18End: 2029-05-25Target: 8100Updated: 2024-12-16
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
Active, not recruitingNCT05314023
Merck Sharp & Dohme LLCGenital Warts
Start: 2022-05-07End: 2029-02-19Target: 1590Updated: 2023-01-19
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
Active, not recruitingNCT05450705
Merck Sharp & Dohme LLCPapillomavirus Infections
Start: 2022-07-22End: 2029-08-03Target: 1500Updated: 2022-09-02

Related Papers

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.
2025-10-06
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine
Vaccine2025-07-31
Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201.
2025-07-02
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine
Expert Review of Vaccines2025-03-184 citations
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
Human Vaccines & Immunotherapeutics2025-01-223 citations
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine
PEDIATRICS2024-07-097 citations
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men.
2021-10-1920 citations
Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals.
2021-04-124 citations
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
Human Vaccines & Immunotherapeutics2021-04-122 citations